Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Imugene ( (AU:IMU) ).
Imugene Limited has notified the market of the issue of new unquoted securities, comprising 25 new convertible notes and 7,812,500 new warrants, with an issue date of 18 December 2025. These instruments, which are not intended to be quoted on the ASX, form part of previously announced transactions and indicate the company is continuing to utilise structured financing to support its operations and development programs, with potential future dilution implications for existing shareholders depending on conversion and exercise terms.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australian biotechnology company listed on the ASX that focuses on developing novel immuno-oncology therapies, leveraging its research to target various cancers and expand its pipeline of clinical-stage and preclinical assets in global oncology markets.
YTD Price Performance: -75.76%
Average Trading Volume: 1,891,756
Technical Sentiment Signal: Sell
Current Market Cap: A$96.19M
See more data about IMU stock on TipRanks’ Stock Analysis page.